Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

Eyenovia Inc. (NASDAQ: EYEN), an ophthalmic technology company, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15th, 2024. The company's pre-recorded presentation will be available on-demand starting at 7:00 am EDT on the conference day.

Eyenovia is known for commercializing Mydcombi™, an ophthalmic spray for mydriasis, and clobetasol propionate ophthalmic suspension for postsurgical inflammation and pain. They are also developing the Optejet® device for pediatric progressive myopia and dry eye treatments, with potential for out-licensing in additional indications.

Investors and interested parties can access the presentation by registering for the conference. Virtual 1x1 meetings with Eyenovia management can be arranged through H.C. Wainwright representatives.

News Market Reaction – EYEN

-9.08%

-9.08% Session move

In the trading session that priced this news, EYEN declined 9.08%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, clobetasol propionate ophthalmic suspension, 0.05% for postsurgical inflammation and pain, and developing the Optejet® device for use both in connection with its own drug-device therapeutic product for pediatric progressive myopia and dry eye as well as out-licensing for additional indications, today announced that the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15^th.

Management’s pre-recorded company presentation can be accessed on-demand beginning at 7:00 am EDT on the day of the conference.

For additional information, or to register for the conference, please click here. To arrange a virtual 1x1 meeting with Eyenovia management, please contact your H.C. Wainwright representative.

PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

PLEASE GO TO CLOBETASOLBID.COM FOR IMPORTANT SAFETY INFORMATION for Clobetasol Proprionate Ophthalmic Suspension 0.05%

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery, which was approved by the FDA on March 4, 2024.

Eyenovia is also advancing late-stage development of MicroPine for pediatric progressive myopia (partnered with Arctic Vision in China and South Korea).

For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

FAQ

When is Eyenovia (EYEN) participating in the H.C. Wainwright Ophthalmology Conference?

Eyenovia (EYEN) is participating in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15th, 2024.

What time will Eyenovia's (EYEN) presentation be available at the conference?

Eyenovia's (EYEN) pre-recorded company presentation will be available on-demand starting at 7:00 am EDT on the day of the conference, August 15th, 2024.

What products is Eyenovia (EYEN) currently commercializing?

Eyenovia (EYEN) is currently commercializing Mydcombi™, an ophthalmic spray for mydriasis, and clobetasol propionate ophthalmic suspension for postsurgical inflammation and pain.

What is Eyenovia (EYEN) developing with its Optejet® device?

Eyenovia (EYEN) is developing the Optejet® device for use in pediatric progressive myopia and dry eye treatments, with potential for out-licensing in additional indications.

How can investors arrange meetings with Eyenovia (EYEN) management during the conference?

Investors can arrange virtual 1x1 meetings with Eyenovia (EYEN) management by contacting their H.C. Wainwright representative.